Matinas BioPharma is a clinical stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life threatening infections. The Company s proprietary, disruptive technology utilizes lipid crystal nano particle cochleates to nano encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company s lead drug candidate is MAT , an orally administered, encochleated formulation of amphotericin B a broad spectrum fungicidal agent . The Company has an open Investigational New Drug IND application for MAT , which is an orally administered, encochleated formulation of amikacin a broad spectrum aminoglycoside antibiotic agent for acute bacterial infections, including non tuberculous mycobacterium NTM and multi drug resistant gram negative bacterial infections. For more information, please visit www.matinasbiopharma.com lt / td gt
Quote | Matinas Biopharma Holdings Inc. (NYSE:MTNB)
Last: | $0.2717 |
---|---|
Change Percent: | -6.28% |
Open: | $0.2801 |
Close: | $0.2899 |
High: | $0.2866 |
Low: | $0.271 |
Volume: | 1,033,613 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Matinas Biopharma Holdings Inc. (NYSE:MTNB)
2024-03-27 16:46:08 ET More on Matinas Biopharma Seeking Alpha’s Quant Rating on Matinas Biopharma Historical earnings data for Matinas Biopharma Financial information for Matinas Biopharma Read the full article on Seeking Alpha For further det...
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasiv...
Message Board Posts | Matinas Biopharma Holdings Inc. (NYSE:MTNB)
Subject | By | Source | When |
---|---|---|---|
Lets go go go go... Up up and away we go. | dhbuzz | investorshub | 05/08/2023 6:16:46 PM |
news all the way baby | dhbuzz | investorshub | 05/06/2023 3:00:33 PM |
$MTNB bears and bulls | RealFooFighters | investorshub | 05/05/2023 6:39:58 AM |
MomentumIts trading | RealFooFighters | investorshub | 05/02/2023 8:01:29 AM |
best news of the day | The Lawman | investorshub | 05/01/2023 2:25:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership dis...
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasiv...
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data from prior in vivo study of oral LNC-docetaxel showing reductio...